Board of Directors

Dr. Harriman has over 25 years of experience with increasing responsibilities in academic medicine and the biopharmaceutical industry. He has held leadership positions in both small and large biopharmaceutical companies, having global responsibilities in research and development of pharmaceuticals, biologics, medical devices and cell therapies. Dr. Harriman founded Main Line Ventures, an investment and consultancy company focused on identifying innovative and pioneering life sciences opportunities. He is a member of Robin Hood Ventures, an angel investing group, and he works closely with the life sciences community in the Philadelphia area to identify and fund biotech companies and to advance translational medical research. He received his medical degree at the University of California, San Diego and trained in internal medicine at Barnes Hospital and completed a fellowship in infectious diseases at the NIH.

Maria Maccecchini received her PhD in biochemistry from Rockefeller University and spent two years at Caltech as a postdoc in molecular biology. Her first industry position was at Mallickrodt as research scientist. Subsequently, she served as general manager of Bachem Bioscience, a US subsidiary of a Swiss company. In the early 1990s, Dr. Maccecchini established Symphony Pharmaceuticals. After acquiring the Scottish and Japanese company Cruachem, Symphony Pharmaceuticals changed its name to Annovis. Annovis develops, manufactures, and markets a variety of nucleic acid-based products and services for businesses in the life sciences sector. In 2001, Annovis was acquired by Transgenomic Inc. of San Jose, CA. Dr. Maccecchini serves on several boards of biotechnology companies, organizations that promote entrepreneurship, international trade as well as women and charitable organizations. Currently she is a member and director of two angel funds – Robin Hood Ventures and Mid-Atlantic Angel Group.

Mr. McIntosh is a 30+-year veteran of the pharmaceutical, biotechnology, diagnostics and device industries. Most recently, he was Chief Operating Officer, Neuro Hitech, Inc. He began his career at Merck and Co., Inc. where for 15 years he served in 11 different positions including Director of Business Development, and Sr. Director of Marketing Antibiotics/Vaccines. He served in senior management positions at a variety of pharmaceutical and biotechnology companies including Medco Containment Services, Boehringer Mannheim Pharmaceuticals Corporation, Zynaxis, Inc., Glaxo SmithKline, and VIMRx, Inc. In addition, he was CEO for Nexell Therapeutics, Inc. and Q-RNA, Inc. Mr. McIntosh has both a B.S. and M.B.A. from Lehigh University.

Mr. Williamson is a 30+ year veteran of the pharmaceutical and biotechnology industry with a focus on sales, marketing, business development, commercial operations, fund raising, senior management and board positions. He has had broad experience with large and medium pharmaceutical companies, biotechnology, and start-up stage companies. Mr. Williamson began his career at Merck and Co., Inc. where he served in a variety of positions for over 15 years. After leaving Merck, Mr. Williamson has served in senior management positions at Genentech, Inc., Boehringer Mannheim Pharmaceuticals, CTRC Institute for Drug Development, ILEX Oncology, Inc., Advagen, Inc. and Systems Medicine, Inc.

Dr. Wong is a 25-year veteran of the pharmaceutical, biotechnology, diagnostics and device industries. He most recently served as Chief Scientific Officer at Neuro-Hitech, Inc. Over his career he has served as a senior manager at Becton-Dickinson Corporation, E. I. DuPont Company, Zynaxis, Inc., Intracel Corporation, Nexell Therapeutics, Inc. and Lynx Therapeutics, Inc. Dr. Wong received his Ph.D. from the University of Rochester, School of Medicine in the Department of Microbiology and Immunology.